Increased Bioavailability of Nitric Oxide After Lipid-Lowering Therapy in Hypercholesterolemic Patients
Key result
Fluvastatin significantly improved endothelium-dependent vasodilation compared with placebo (change of 108% vs -26%; P≤0.05), an effect mediated by increased nitric oxide bioavailability.
Why the study?
Does fluvastatin improve endothelium-dependent vasodilation in patients with hypercholesterolemia?
Population
29 patients with hypercholesterolemia (LDL cholesterol >= 160 mg/dL), mean age 50+/-12 years
Comparison
Fluvastatin 40 mg twice daily for 24 weeks vs Placebo
Design
RCT, randomly assigned, double-blind, placebo-controlled
Follow-up
24 weeks
Authors
Discussion
Loading...
Member takes
Implication
Supports fluvastatin for endothelial protection in hypercholesterolemia; extends statin evidence to nitric oxide bioavailability.
Study Design
Type
RCT (n=29)
Blinding
double-blind
Randomization
randomized
Structured PICO
Does fluvastatin improve endothelium-dependent vasodilation in patients with hypercholesterolemia?
P
Population
29 patients (mean age 50) with hypercholesterolemia (LDL cholesterol ≥ 160 mg/dL) randomized to fluvastatin or placebo for 24 weeks.
I
Intervention
Fluvastatin 40 mg twice daily for 24 weeks
C
Comparator
Placebo
O
Outcome
Endothelium-dependent vasodilation assessed by intra-arterial infusion of acetylcholine and forearm blood flow by plethysmography at 24 weekssurrogate
Main Result
Absolute Event Rate: 108% vs -26%
p-value: p=≤0.05
Fluvastatin improves endothelial function in hypercholesterolemic patients by increasing the bioavailability of nitric oxide.
Cite This Study
John et al. (1998) conducted an RCT in Hypercholesterolemia (n=29). Fluvastatin vs. Placebo was evaluated on Change in endothelium-dependent vasodilation (ACh 24 microg/min) (p=≤0.05). Fluvastatin significantly improved endothelium-dependent vasodilation compared with placebo (change of 108% vs -26%; P≤0.05), an effect mediated by increased nitric oxide bioavailability.